Prime Medicine, Inc. (PRME)
Prime Medicine, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Prime Medicine, Inc. (PRME) is a Biotechnology company based in US with a market capitalization of $563.5M. Free cash flow was negative at -$167.1M. This page tracks PRME's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 214 employees · IPO Oct 20, 2022
Valuation
Valuation & price
$4.23as of Jul 10, 2026· -36.6% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
4.66
P/B ratio
Market cap ÷ book equity
No dividend
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$563.5M
Market cap
—
Revenue growth (YoY)
-58.0%
Gross margin
-$167.1M
Free cash flow (USD)
-$61.3M
Net debt
Net cash position
25.4%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2019 → 2025
Free cash flow by year
2019 → 2025
Gross margin by year
2024 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 7, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is Prime Medicine, Inc.'s market cap?
Prime Medicine, Inc. (PRME) has a market capitalization of $563.5M.
What is PRME's P/E ratio?
A meaningful P/E ratio is not available for PRME — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is PRME's price-to-book (P/B) ratio?
PRME trades at 4.66 times book value per share.
Does Prime Medicine, Inc. pay a dividend?
No — PRME did not pay a dividend in its latest reported fiscal year.
Are insiders buying PRME stock?
SEC Form 4 filings show no open-market insider buys at Prime Medicine, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.